MARKET

XXII

XXII

22Nd Century
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.850
+0.020
+1.09%
Closed 19:27 05/26 EDT
OPEN
1.840
PREV CLOSE
1.830
HIGH
1.900
LOW
1.800
VOLUME
589.39K
TURNOVER
--
52 WEEK HIGH
5.25
52 WEEK LOW
1.420
MARKET CAP
304.39M
P/E (TTM)
-8.2076
1D
5D
1M
3M
1Y
5Y
Cannabis Stock Gainers And Losers From May 25, 2022
GAINERS: Item 9 Labs (OTC:INLB) shares closed up 9.00% at $1.09
Benzinga · 1d ago
Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International
Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department.
Benzinga · 3d ago
22nd Century Group (Nasdaq: XXII) Announces John J. Miller Joins Its Tobacco Business
Highly Regarded for His Extensive Sales and Marketing Experience in the Tobacco Industry Expands and Further Strengthens the Company’s Team of Tobacco Industry Experts BUFFALO, N.Y., May 23, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII),...
GlobeNewswire · 4d ago
BRIEF-22Nd Century Group Inc - Begun Integration Of GVB Biopharma, Which It Acquired On May 13, 2022
reuters.com · 05/18 22:05
Marijuana Stock Movers For May 18, 2022
GAINERS: Item 9 Labs (OTC:INLB) shares closed up 21.21% at $1.00
Benzinga · 05/18 20:36
22nd Century Group Reports Will Begin Integration Of GVB Biopharma
Complete Hemp/Cannabis Solution from Receptor Science and Plant Genetics to Final Ingredients and CDMO Consistent, Reliable, High-Quality Cannabinoids and Cannabinoid Infused Products for Consumers Acquisition
Benzinga · 05/18 20:35
Cannabis Stock Gainers And Losers From May 16, 2022
GAINERS: Sundial Growers (NASDAQ:SNDL) shares closed up 21.09% at $0.47
Benzinga · 05/16 20:49
Clarence's 22nd Century Group acquires Las Vegas-based hemp/cannabis company
The acquisition of GVB BioPharma will boost the research efforts of the Clarence biotech company — known for developing a low-nicotine cigarette — in the hemp and cannabis space.
American City Business Journals · 05/13 18:08
More
No Data
Learn about the latest financial forecast of XXII. Analyze the recent business situations of 22Nd Century through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average XXII stock price target is 6.50 with a high estimate of 8.50 and a low estimate of 5.00.
High8.50
Average6.50
Low5.00
Current 1.830
EPS
Actual
Estimate
-0.07-0.05-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 166
Institutional Holdings: 47.92M
% Owned: 29.12%
Shares Outstanding: 164.54M
TypeInstitutionsShares
Increased
30
1.27M
New
14
1.19M
Decreased
40
2.84M
Sold Out
16
263.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Tobacco
-0.22%
Food & Tobacco
+0.78%
Key Executives
Non-Executive Chairman/Independent Director
Nora Sullivan
President/Chief Operating Officer
Michael Zercher
Chief Executive Officer/Director
James Mish
Chief Financial Officer
Richard Fitzgerald
Chief Administrative Officer
John Franzino
Vice President
John Brodfuehrer
Vice President - Research & Development
Juan Tamburrino
Independent Director
Clifford Fleet
Independent Director
Anthony Johnson
Independent Director
Michael Koganov
Independent Director
Roger O'Brien
Independent Director
Richard Sanders
No Data
No Data
About XXII
22nd Century Group, Inc. is a biotechnology company. The Company is developing plant-based solutions for the life science, consumer product and pharmaceutical markets. It is focused on the technology that modulate the level of nicotine and other nicotinic alkaloids in tobacco plants and the levels of cannabinoids and terpenes in hemp/cannabis plants through genetic engineering and modern plant breeding techniques. In tobacco, it has developed very low nicotine content (VLNC) tobaccos that grow with approximately 95% less nicotine than tobacco used in conventional cigarettes. It has developed SPECTRUM, is a variable nicotine research cigarette through various independent researchers. It has developed a VLN 2.0 prototype cigarette through its non- genetically modified (GMO) technology. In hemp/cannabis, it is developing hemp/cannabis varieties with increased levels of certain cannabinoids and other agronomic traits.

Webull offers kinds of 22nd Century Group Inc stock information, including NASDAQ:XXII real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XXII stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XXII stock methods without spending real money on the virtual paper trading platform.